Lexaria Bioscience Corp. (LEXX)
Market Cap | 8.09M |
Revenue (ttm) | 340,791 |
Net Income (ttm) | -6.89M |
Shares Out | 8.09M |
EPS (ttm) | -1.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 50,196 |
Open | 0.850 |
Previous Close | 0.970 |
Day's Range | 0.850 - 1.000 |
52-Week Range | 0.649 - 3.595 |
Beta | 1.14 |
Analysts | Strong Buy |
Price Target | 2.00 (+100.02%) |
Earnings Date | Jul 14, 2023 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, ant... [Read more]
Financial Performance
In 2022, LEXX's revenue was $255,397, a decrease of -64.66% compared to the previous year's $722,738. Losses were -$7.27 million, 80.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price forecast is $2.0.
News

Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
KELOWNA, BC / ACCESSWIRE / September 29, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that i...

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as: Reduced side effects; Enhanced weight loss; Improved health outcomes for diabetes and other conditions; Improved o...

Lexaria Provides Update on Investigational New Drug Application Progress
KELOWNA, BC / ACCESSWIRE / August 30, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update ...

Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1 Noteworthy superior subjective performance characte...

Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to report its in...

Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporate...

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
More countries are banning e-cigarettes as novel oral products gain traction KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"...

Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
DehydraTECH-CBD now featured in eight published, peer-reviewed papers KELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a gl...

Lexaria Receives New Patents
Total of 6 new granted patents received by Lexaria so far in 2023 Lexaria now holds 34 granted patents world-wide KELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASD...

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Blood glucose levels reduced by 19.9% with DehydraTECH-CBD Improvements in kidney function also demonstrated KELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LE...

Lexaria Appoints New Chief Financial Officer
KELOWNA, BC / ACCESSWIRE / June 12, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of...

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "...

Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH KELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),...

Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing ...

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations. DehydraTECH-CBD has demonstrated exceptional safety and tolerability and ...

Lexaria Announces 2023 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / May 10, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the ...

Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the pricing ...

Lexaria's Human Clinical Nicotine Study Completes Dosing as Planned
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing of the t...

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertension California-based InClin to provide CRO services to manage and exped...

Lexaria is Receiving Four New Patents
KELOWNA, BC / ACCESSWIRE / April 20, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has recei...

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
KELOWNA, BC / ACCESSWIRE / March 2, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its diabetes...

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce...

Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
KELOWNA, BC / ACCESSWIRE / January 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce th...

Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESSWIRE / January 13, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide an...

Lexaria Receives First Granted Patent in Canada
KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce i...